Celularity (CELU) Accounts Payables (2018 - 2025)
Celularity (CELU) posted quarterly Accounts Payables of $26.4 million for Q4 2025, up 13.42% year-over-year from $23.3 million in Q4 2024, and up 7.46% quarter-over-quarter from $24.6 million in Q3 2025.
Celularity (CELU) Accounts Payables (2018 - 2025) Analysis & Trends
Celularity (CELU) has reported Accounts Payables for 8 consecutive years, with $26.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Accounts Payables rose 13.42% year-over-year to $26.4 million; the TTM figure through Dec 2025 stood at $26.4 million (up 13.42% YoY), while the FY2025 annual figure was $26.4 million, up 13.42% from the prior year.
- Accounts Payables rose to $26.4 million in Q4 2025 per CELU's latest filing, from $24.6 million in the prior quarter.
- Across five years, Accounts Payables topped out at $26.4 million in Q4 2025 and bottomed at $5.0 million in Q1 2021.
- Historically, Accounts Payables has averaged $13.8 million across 5 years, with a median of $12.7 million in 2023.
- Annual changes were most pronounced in 2021 — Accounts Payables soared 12694.08% — and 2022, when it slumped 37.64%.
- Celularity's Accounts Payables stood at $9.3 million in 2021, then sank by 37.64% to $5.8 million in 2022, then soared by 143.44% to $14.1 million in 2023, then surged by 64.71% to $23.3 million in 2024, then advanced by 13.42% to $26.4 million in 2025.
- Business Quant data shows CELU's Accounts Payables at $26.4 million in Q4 2025, $24.6 million in Q3 2025, and $24.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.65 Bn | 131.79 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.08 Bn | 78.09 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.16 Bn | 59.98 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 63.25 Bn | 58.11 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.26 Bn | 27.95 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.96 Bn | 10.57 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.19 Bn | 26.35 Bn | - | 35.57 Mn |
| 10 | Celularity | 21.76 Mn | 15.58 Mn | -3.27 Mn | 26.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 26.42 Mn |
| Sep 30, 2025 | 24.59 Mn |
| Jun 30, 2025 | 24.40 Mn |
| Mar 31, 2025 | 23.31 Mn |
| Dec 31, 2024 | 23.30 Mn |
| Sep 30, 2024 | 15.40 Mn |
| Jun 30, 2024 | 13.73 Mn |
| Mar 31, 2024 | 12.98 Mn |
| Dec 31, 2023 | 14.14 Mn |
| Sep 30, 2023 | 12.93 Mn |
| Jun 30, 2023 | 12.45 Mn |
| Mar 31, 2023 | 8.76 Mn |
| Dec 31, 2022 | 5.81 Mn |
| Sep 30, 2022 | 9.22 Mn |
| Jun 30, 2022 | 10.23 Mn |
| Mar 31, 2022 | 10.42 Mn |
| Dec 31, 2021 | 9.32 Mn |
| Sep 30, 2021 | 7.03 Mn |
| Jun 30, 2021 | 6.18 Mn |
| Mar 31, 2021 | 5.04 Mn |